HIGHLIGHTS
- who: GUIDELINES and collaborators from the (UNIVERSITY) have published the paper: Severe atopic dermatitis and dupilumab, in the Journal: (JOURNAL)
- what: In this analysis , 1,773 patients submitted to dupilumab and 1,684 to placebo were studied.
SUMMARY
Nine randomized 2 Rev Assoc Med Bras 2023;69(1):2-6 RESULTS BY OUTCOMES clinical trials were included to support the analyses and conclusions of this review1-9. A total of 2,606 patients submitted to dupilumab and 1,441 submitted to placebo were analyzed. The outcomes analyzed were: Eczema Area and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.